The association between methionine synthase A2756G polymorphism and hematological cancer: A meta-analysis

    loading  Checking for direct PDF access through Ovid



Numerous studies have focused on the association of methionine synthase (MS) A2756G polymorphism and acute hematological cancer risk. However, the results remain inconsistent. Therefore, a meta-analysis was performed to derive a more precise estimate of the association between them.


This meta-analysis involved 25 articles (26 studies) including 8641 hematological cancer patients and 15,498 controls. The pooled odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) of the association between MS A2756G polymorphism and the risk of hematological cancer were calculated.


Overall, no significant increased risks were found between MS A2756G polymorphism and hematological cancer risk under allelic homozygote (GA vs AA: OR = 0.98, 95% CI = 0.89–1.07, P = .62), heterozygote (GG vs AA: OR = 0.99, 95% CI = 0.85–1.15, P = .91), dominant (AG+GG vs AA: OR = 0.99, 95% CI = 0.90–1.08, P = .93), and recessive (GG vs AG+AA: OR = 1.00, 95% CI = 0.86–1.16, P = .97) models, respectively. In the stratified analyses by ethnicity and source of controls, there were still no significant associations between them in all genetic models.


Therefore, these findings demonstrate that MS A2756G polymorphism may not be a risk factor for hematological cancer.

Related Topics

    loading  Loading Related Articles